3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Breast
15
Gastrointestinal
3
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Surveys and Questionnaires
52
Blood Specimen Collection
47
enzalutamide
29
radium Ra 223 dichloride
22
Biopsy
20
darolutamide
19
Radiotherapy
19
Docetaxel
19
apalutamide
18
Sunitinib
18
Magnetic Resonance Spectroscopy
18
Sorafenib
17
Abiraterone Acetate
17
Watchful Waiting
16
Interviews as Topic
15
Gene Expression Profiling
15
Amplified Fragment Length Polymorphism Analysis
15
Observation
13
Leuprolide
13
Immunohistochemistry
13
Androgen Antagonists
13
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
12
Magnetic Resonance Imaging
12
avelumab
11
Specimen Handling
11
abiraterone
9
Polymerase Chain Reaction
9
Flow Cytometry
9
Radiosurgery
8
Microarray Analysis
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled